Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8662610 | 0.85 | NPC1 (0.45) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL8664446 | 0.85 | F2 (0.44) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL787248 | 0.84 | TSHR (0.44) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL27584031 | 0.84 | CA1 (0.43) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL5931092 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL571764 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL3442045 | 0.77 | CA1 (0.56) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL28271705 | 0.76 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL20521612 | 0.76 | GAA (0.48) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL24334208 | 0.76 | ALDH1A1 (0.54) | ALDH1A1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569294-B1 | Use of an arylsulfonylurethane as strengthening resin in nitrocellulose nail lacquers, arylsulfonylurethanes and nitrocellulose nail lacquers | POUDRES & EXPLOSIFS STE NALE (FR) | 1996-07-17 | — | — | EP | claimed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023168066-A9 | OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023168066-A1 | OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2022261257-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021146553-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20200223884-A1 | 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20190350931-A1 | COMBINATION THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-21 | — | — | US | disclosed |
| EP-2598170-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015681-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350931-A1 | COMBINATION THERAPY | PRMT1, PRMT6, PRMT3 | ALDH1A1 3876/4885CA1 2138/4885CA2 1907/4885 |
| US-20200223884-A1 | 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | HSD3B1, HSD3B2, CYP11B1 | ALDH1A1 495/4885CA1 2056/4885CA2 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.